By Denny Jacob
Actuate Therapeutics said its treatment for Ewing sarcoma was granted rare pediatric-disease designation from the Food and Drug Administration.
Chief Executive Daniel Schmitt said early clinical data from the ongoing Phase 1/2 trial of elraglusib shows promising anti-tumor activity with objective tumor responses.
Ewing sarcoma is a highly metastatic form of sarcoma that originates in bone with a peak incidence at the age of 15, the clinical-stage biopharmaceutical company said.
The FDA's pediatric-disease designation is granted for serious or life-threatening ailments that affect fewer than 200,000 people in the U.S., and which the serious or life-threatening manifestations primarily affect individuals less than 18 years old.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
November 12, 2024 08:34 ET (13:34 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。